Table 2. Number of samples analyzed for each histological type and the number of mutations identified.
| Tumor type | Histotype | Number of samples analysed | Number of GNAQ mutated samples | P-value Fisher's exact test) |
| Blue neavi | 13 | 6 | ||
| AML | 80 | 0 | 2,25E-06 | |
| Bladder | Total | 39 | 0 | 8,42E-05 |
| transitional cell carcinoma | 35 | 0 | ||
| cell line | 4 | 0 | ||
| Breast | Total | 148 | 0 | 7,79E-08 |
| ductal carcinoma | 61 | 0 | ||
| lobular carcinoma | 50 | 0 | ||
| medullary carcinoma | 18 | 0 | ||
| mucinous carcinoma | 19 | 0 | ||
| Colorectal | adenocarcinoma | 119 | 0 | 2,62E-07 |
| GIST | 22 | 0 | 1,06E-03 | |
| Glioma | Total | 131 | 0 | 1,54E-07 |
| glioblastoma | 117 | 0 | ||
| anaplastic astrocytoma | 2 | 0 | ||
| anaplastic oligodendroglioma | 2 | 0 | ||
| high grade glioma cell lines | 14 | 0 | ||
| Lung | Total | 134 | 0 | 1,36E-07 |
| adenocarcinoma | 110 | 0 | ||
| small cell carcinoma | 17 | 0 | ||
| carcinoid | 7 | 0 | ||
| Melanoma | Total | 24 | 0 | 7,38E-04 |
| primary | 1 | 0 | ||
| nodal metastasis | 14 | 0 | ||
| cutaneous metastasis | 7 | 0 | ||
| visceral metastasis | 2 | 0 | ||
| Ovary | serous adenocarcinoma | 51 | 0 | 2,28E-05 |
| Pancreas | ductal adenocarcinoma | 98 | 0 | 7,57E-07 |
| Thyroid | Total | 63 | 0 | 7,85E-06 |
| medullary carcinoma | 23 | 0 | ||
| papillary carcinoma | 20 | 0 | ||
| follicular carcinoma | 20 | 0 |
(AML: acute myeloid leukemia, GIST: Gastrointestinal Stromal Tumors; In addition, p-values of the Fisher's exact test, used to determine the tissue specificity for GNAQ Q209 mutations in blue naevi, are listed.)